Biomarker for predicting adverse events of tumor immune checkpoint blocking treatment and application of biomarker

• Main Authors: RONG ZIXUAN, DONG ZHONGYI, MA SICONG, LIN JIARUN, WU DEHUA, BAI XUE
• Format: Patent
• Language: Chinese; English
• Published: 17.03.2023
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention discloses a biomarker for predicting adverse events of tumor immune checkpoint blocking treatment and application of the biomarker, and relates to the field of biomedicine. The biomarker is a CRTAM gene, and the nucleotide sequence of the biomarker is as shown in SEQ ID NO. 1. Analysis discovers that the expression level of the CRTAM is significantly positively correlated with the adverse events of the immune checkpoint blocking treatment, the ligand CADM1 of the non-tumor tissue high expression CRTAM significantly interacts with CRTAM + T cells, and finally, the prediction value of the baseline CRTAM on the adverse events of the immune checkpoint blocking treatment is verified in a melanoma immunotherapy queue. The biomarker provided by the invention provides a scientific basis for early recognition of immune checkpoints to block treatment of high-risk groups of adverse events, brings more clinical benefits to tumor patients, and has important clinical significance. 本发明公开了一种用于预测肿瘤免疫检查点阻断治疗不良事件的